Bharat Biotech begins clinical trials of TB vaccine on adults in India

Mar24,2024



Hyderabad: Bharat Biotech International Limited said on Sunday that it has started clinical trials of tuberculosis vaccine mtb style On adults in India.
It is the first vaccine against tuberculosis derived from a human source, by a Spanish biopharmaceutical company. biofabriBharat Biotech said in a press release.
The release states that MountBvac is being developed for two purposes; First, as a more effective and potentially longer-lasting vaccine than BCG (Bacillus Calmette Guerin) for newborns and second, for the prevention of TB in adults and adolescents, for whom there is currently no effective vaccine. Not there.
The trials have been conducted by Bharat Biotech in close collaboration with Biofabri. The release said trials to evaluate the safety and immunogenicity of MTBVac have begun with a pivotal safety, immunogenicity and efficacy trial planned to begin in 2025.
This is a major step forward for testing among adults and adolescents in a country that accounts for 28 percent of the world's TB cases.
Esteban Rodriguez, CEO of Biofabri, said TB is one of the leading infectious causes of death in the world, especially in India. Krishna Ella, Executive Chairman, Bharat Biotech, said, “Our quest for a more effective vaccine against tuberculosis has received a major boost today with clinical trials underway in India. Our efforts to develop TB vaccines to prevent the disease in adults and adolescents Lakshya has taken a big step today.” ,
The MtbVac vaccine has crossed several milestones before entering clinical trials in India. Following the recent completion of the Phase-2 dose-finding trial, a double-blind controlled Phase-3 clinical trial in neonates has been initiated in 2023 to compare the vaccine with the existing BCG vaccine .
7,000 newborns from South Africa, 60 from Madagascar and 60 from Senegal will be vaccinated. More than 1,900 infants have been vaccinated so far, the release said.



Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *